Gastrointestinal Effects Nausea (12 to 18%), diarrhea (12 to 17%), and vomiting (5 to 9%) in SURPASS trials arise predominantly from GLP-1R activation on vagal afferents and NTS neurons [14]
They address underlying issues like metabolic imbalances, food sensitivities, and nutrient deficiencies
These higher dosages are possible to achieve in mice, since they cannot complain to scientists about side effects occurring at high dosages and do not have the physical capability to prevent themselves from receiving drug injections) Sanofi produced a triple agonist , SAR441255, which was capable of decreasing body weight in mice by around 14% at 26 days, 12% in monkeys by 42 days [34] , although Sanofi have since discontinued development of the triple agonist for human use for uncited reasons
Because data shows that women experience nausea and vomiting at up to 2.5 times the rate of men while on GLP-1 agonists (possibly due to higher GLP-1 receptor expression in female brain regions associated with nausea), microdosing GLP-1 medications could potentially help lower the likelihood of these effects
:max_bytes(150000):strip_icc()/VWH-GettyImages-2126120259-c2442d334436484baa255439265b7fb1.jpg)
